Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 6Neoplasms by Site 2Neoplasms 2Neoplasm Metastasis 2Breast Diseases 2Skin Diseases 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer 1Advanced Prostate Cancer 1

Interventions

pembrolizumab 3entrectinib 2zanidatamab 1trastuzumab deruxtecan 1spartalizumab 1neratinib 1larotrectinib 1cevimeline 1apalutamide 1alectinib 1Tablets 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Gonadotropin-Releasing Hormone 1Fentanyl 1EBC-46 1Drug Therapy 1Docetaxel 1Combined Modality Therapy 1Carboplatin 1Biological Therapy 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Salivary Gland Neoplasms × Gonadotropin-Releasing Hormone × Clear all
NCT04325828 2026-05-08

YATAGARASU

Janssen Pharmaceutical K.K.

Phase 2 Active not recruiting
31 enrolled 15 charts
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡